Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Madrigal Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company develops novel and small-molecule drugs addressing cardiovascular and metabolic diseases. Madrigal Pharmaceuticals offers its services in the United States.
Website: madrigalpharma.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 16.7%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -4 337.5%. On average the margin is decreasing steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.1 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 296.7% higher than minimum and 20.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -198.8x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $59.0 mln (-0.595% of cap.)

Key Financials (Download financials)

Ticker: MDGL
Share price, USD:  (+3.1%)477.6
year average price 399.36  


year start price 332.72 2025-02-08

min close price 267.56 2025-05-23

max close price 602.83 2025-12-22

current price 477.60 2026-02-07
Common stocks: 18 476 414

Dividend Yield:  0.0%
EV / Sales: 1 075.3x
Margin (EBITDA LTM / Revenue): -4 337.5%
Fundamental value created in LTM:
Market Cap ($m): 8 824
Net Debt ($m): -222
EV (Enterprise Value): 8 602
Price to Book: 14.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-02globenewswire.com

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026

2026-01-13seekingalpha.com

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-11-20seekingalpha.com

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-05zacks.com

Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up

2025-11-04seekingalpha.com

Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript

2025-10-28zacks.com

Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?

2025-10-26seekingalpha.com

Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued Growth

2025-10-16youtube.com

Madrigal Pharma CEO talks competition in the liver disease treatment space

2025-09-08seekingalpha.com

Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

2025-08-20zacks.com

Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-04 2025-08-05 2024-10-31 2024-08-07 2024-05-07 2023-11-06 2023-08-08 2023-05-09 2022-11-03
acceptedDate 2025-11-04 09:11:38 2025-08-05 08:59:23 2025-02-26 09:09:31 2024-10-31 09:02:50 2024-08-07 08:58:48 2024-05-07 09:00:37 2024-02-28 06:32:35 2023-11-06 06:10:12 2023-08-08 06:50:49 2023-05-09 06:51:22 2023-02-23 06:32:29 2022-11-03 08:56:24 2022-02-24 13:39:52 2021-02-25 11:05:24
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 287M 213M 180M 62M 15M 0 0 0 0 0 0 0 0 0
costOfRevenue 18M 9M 6M 2M 903 000 168 000 0 135 000 126 000 0 0 0 0 471 000
grossProfit 269M 204M 174M 60M 14M -168 000 0 -135 000 -126 000 0 0 0 0 -471 000
grossProfitRatio 0.937 0.957 0.965 0.938 0 0 0 0 0
researchAndDevelopmentExpenses 174M 54M 237M 69M 71M 71M 272M 71M 69M 62M 245M 68M 205M 185M
generalAndAdministrativeExpenses 209M 0 0 108M 105M 81M 108M 28M 18M 16M 48M 12M 37M 22M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 209M 197M 435M 108M 105M 81M 108M 28M 18M 16M 48M 12M 37M 22M
otherExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
operatingExpenses 383M 251M 672M 176M 176M 152M 380M 99M 86M 78M 294M 80M 242M 206M
costAndExpenses 401M 260M 678M 178M 177M 152M 380M 99M 86M 78M 294M 80M 242M 207M
interestIncome 10M 8M 47M 13M 14M 8M 20M 3M 4M 4M 2M 717 000 363 000 4M
interestExpense 7M 3M 15M 4M 4M 4M 13M -4M 3M 2M 4M 2M 0 0
depreciationAndAmortization 358 000 377 000 1M 298 000 267 000 168 000 527 000 135 000 126 000 4M 467 000 838 000 405 000 471 000
ebitda -106M -39M -450M -103M -148M -152M -360M -99M -83M -74M -291M -80M -241M -202M
ebitdaratio -0.37 -0.182 -1.656 -11.086 0 0 0 0 0
operatingIncome -114M -47M -498M -116M -163M -152M -380M -99M -86M -78M -294M -80M -242M -206M
operatingIncomeRatio -0.397 -0.222 -1.871 -11.104 0 0 0 0 0
totalOtherIncomeExpensesNet -215 000 5M 32M 9M 11M 4M 7M -206 000 650 000 1M -2M -785 000 636 000 4M
incomeBeforeTax -114M -42M -466M -107M -152M -148M -374M -99M -86M -77M -295M -81M -242M -202M
incomeBeforeTaxRatio -0.398 -0.199 -1.72 -10.382 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 0 0 -135 000 3M 896 000 0 2M 0 0
netIncome -114M -42M -466M -107M -152M -148M -374M -99M -86M -78M -295M -83M -242M -202M
netIncomeRatio -0.398 -0.199 -1.72 -10.382 0 0 0 0 0
eps -5.08 -1.9 -21.9 -4.92 -7.1 -7.38 -19.99 -5.34 -4.69 -4.28 -17.23 -4.84 -14.63 -13.09
epsdiluted -5.08 -1.9 -4.92 -7.1 -7.38 -5.34 -4.69 -4.28 -4.84
weightedAverageShsOut 22M 22M 21M 22M 21M 20M 19M 18M 18M 18M 17M 17M 17M 15M
weightedAverageShsOutDil 22M 22M 21M 22M 21M 20M 19M 18M 18M 18M 17M 17M 17M 15M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-28 2023-02-23 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 32M 7M -2M 363 000 4M
ebit -451M -361M -291M -242M -202M
nonOperatingIncomeExcludingInterest -47M -20M -2M -636 000 -4M
netIncomeFromContinuingOperations -466M -374M -295M -242M -202M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -466M -374M -295M -242M -202M
epsDiluted -21.9 -19.99 -17.23 -14.63 -13.09

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-04 2025-08-05 2024-10-31 2024-08-07 2024-05-07 2023-11-06 2023-08-08 2023-05-09 2022-11-03
acceptedDate 2025-11-04 09:11:38 2025-08-05 08:59:23 2025-02-26 09:09:31 2024-10-31 09:02:50 2024-08-07 08:58:48 2024-05-07 09:00:37 2024-02-28 06:32:35 2023-11-06 06:10:12 2023-08-08 06:50:49 2023-05-09 06:51:22 2023-03-03 16:17:47 2022-11-03 08:56:24 2022-02-24 13:39:52 2021-02-25 11:05:24
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 296M 186M 100M 233M 500M 623M 100M 62M 77M 113M 332M 59M 36M 54M
shortTermInvestments 814M 611M 826M 766M 563M 437M 534M 170M 221M 216M 27M 94M 234M 230M
cashAndShortTermInvestments 1 110M 797M 926M 999M 1 063M 1 059M 634M 232M 298M 329M 359M 153M 270M 284M
netReceivables 113M 79M 54M 30M 7M 1 0 0 0 0 0 0 0 0
inventory 69M 63M 34M 9M 7M 854 000 0 0 0 0 0 0 0 0
otherCurrentAssets 54M 64M 19M 26M 20M 14M 3M 3M 3M 2M 3M 4M 0 0
totalCurrentAssets 1 347M 1 003M 1 033M 1 064M 1 092M 1 074M 637M 235M 302M 331M 361M 157M 272M 285M
propertyPlantEquipmentNet 8M 7M 5M 5M 3M 3M 3M 2M 866 000 1M 1M 2M 2M 2M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 7M 5M 5M 5M 5M 5M 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 7M 5M 5M 5M 5M 5M 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 0 0 0 -1 -1 0 0 0 0 0 0 0 0
totalNonCurrentAssets 16M 12M 9M 10M 8M 8M 3M 2M 866 000 1M 1M 2M 2M 2M
otherAssets 0 0 0 0 1 1 0 0 0 0 0 0 0 0
totalAssets 1 362M 1 015M 1 042M 1 073M 1 100M 1 082M 641M 238M 302M 332M 363M 159M 273M 287M
accountPayables 45M 38M 44M 46M 9M 22M 28M 17M 18M 12M 24M 19M 21M 1M
shortTermDebt 1M 1M 0 878 000 557 000 542 000 0 513 000 411 000 653 000 0 760 000 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 345M 157M 35M 131M 116M 92M 17M 83M 82M 86M 15M 80M 7M 5M
totalCurrentLiabilities 391M 197M 169M 178M 125M 114M 119M 100M 100M 98M 116M 99M 77M 47M
longTermDebt 345M 123M 118M 118M 118M 116M 115M 116M 99M 84M 49M 49M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 1M 0 0 0 0 0 30M 0 0
totalNonCurrentLiabilities 345M 123M 119M 118M 118M 117M 117M 116M 99M 84M 49M 49M 387 000 468 000
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 7M 6M 2M 1M 1M 1M 2M 2M 411 000 653 000 602 000 831 000 797 000 786 000
totalLiabilities 737M 319M 288M 296M 243M 232M 235M 216M 199M 182M 165M 148M 77M 47M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000
retainedEarnings -2 032M -1 918M -1 802M -1 743M -1 636M -1 484M -1 336M -1 224M -1 125M -1 040M -963M -877M -667M -425M
accumulatedOtherComprehensiveIncomeLoss 1M 1M 468 000 1M -368 000 -172 000 468 000 -42 000 -89 000 -86 000 -32 000 -237 000 -80 000 47 000
othertotalStockholdersEquity 2 657M 2 613M 2 519M 2 493M 2 335M 1 246M 1 229M 1 190M 888M
totalStockholdersEquity 626M 696M 754M 777M 857M 851M 405M 22M 104M 150M 197M 11M 196M 240M
totalEquity 626M 696M 754M 777M 857M 851M 405M 22M 104M 150M 197M 11M 196M 240M
totalLiabilitiesAndStockholdersEquity 1 362M 1 015M 1 073M 1 100M 1 082M 238M 302M 332M 159M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 362M 1 015M 1 042M 1 073M 1 100M 1 082M 641M 238M 302M 332M 363M 159M 273M 287M
totalInvestments 814M 611M 826M 766M 563M 437M 534M 170M 221M 216M 27M 94M 234M 230M
totalDebt 346M 124M 120M 119M 118M 118M 117M 117M 100M 85M 50M 50M 797 000 786 000
netDebt 51M -62M 20M -114M -382M -505M 17M 55M 22M -29M -282M -10M -35M -53M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-28 2023-03-03 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 54M 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 0 0 0 1M 1M
totalPayables 44M 28M 24M 21M 1M
otherPayables 0 0 0 0 0
accruedExpenses 90M 73M 77M 48M 41M
capitalLeaseObligationsCurrent 983 000 527 000 602 000 410 000 318 000
capitalLeaseObligationsNonCurrent 1M 1M 0 387 000 468 000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 556M 1 741M 1 160M 863M 665M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL MDGL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-04 2025-08-05 2024-10-31 2024-08-07 2024-05-07 2023-11-06 2023-08-08 2023-05-09 2022-11-03
acceptedDate 2025-11-04 09:11:38 2025-08-05 08:59:23 2025-02-26 09:09:31 2024-10-31 09:02:50 2024-08-07 08:58:48 2024-05-07 09:00:37 2024-02-28 06:32:35 2023-11-06 06:10:12 2023-08-08 06:50:49 2023-05-09 06:51:22 2023-03-03 16:17:47 2022-11-03 08:56:24 2022-02-24 13:39:52 2021-02-25 11:05:24
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -114M -42M -466M -107M -152M -148M -374M -99M -86M -77M -295M -81M -242M -202M
depreciationAndAmortization 2M 377 000 696 000 298 000 267 000 168 000 527 000 135 000 126 000 124 000 467 000 121 000 405 000 471 000
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 -7M -22M
stockBasedCompensation 26M 25M 80M 18M 24M 20M 50M 13M 11M 11M 32M 8M 27M 21M
changeInWorkingCapital 163M -32M -72M 22M -8M -22M -3M 351 000 -1M -19M 38M 14M 31M 23M
accountsReceivables -34M -18M -54M -24M -7M 0 0 0 0 0 0 0 0 0
inventory -6M -8M -34M -2M -6M -854 000 0 0 0 0 0 0 0 0
accountsPayables 6M -4M 16M 37M -8M -12M 4M -992 000 5M -12M 2M 7M 20M -161 000
otherWorkingCapital 197M -2M -13 000 10M 13M -10M -7M 1M -7M 12M 35M 6M 10M 24M
otherNonCashItems 2M 1M 2M 22 000 39M 33M 2M 674 000 554 000 433 000 797 000 313 000 7M 22M
netCashProvidedByOperatingActivities 80M -47M -456M -67M -135M -149M -324M -85M -75M -84M -225M -59M -184M -158M
investmentsInPropertyPlantAndEquipment -4M 0 -1M 4M -5M -357 000 -1M -339 000 -69 000 -35 000 -217 000 -33 000 -209 000 -334 000
acquisitionsNet 0 0 0 0 0 0 0 -50 538 3663 -2M -3000 0 787 000 2M
purchasesOfInvestments -478M -226M -1 131M -416M -281M -84M -834M -69M -92M -199M -143M -14M -394M -329M
salesMaturitiesOfInvestments 275M 273M 839M 204M 164M 183M 333M 119M 88M 12M 350M 79M 389M 489M
otherInvestingActivites 0 0 6M -122M 98M 50 538 -3663 2M 0
netCashUsedForInvestingActivites -207M 48M -202M -122M 98M 50M -4M -187M 65M
debtRepayment 219M 0 0 0 0 -15M -15M 0 0
commonStockIssued 18M -9M 7M 86M 574M -21M 28M 18M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 10M 7M 48M 574M 56M 30M 35M 0
netCashUsedProvidedByFinancingActivities 237M 2M 7M 134M 574M 20M 43M 53M 0
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 58M 0 0 0 0 0
netChangeInCash 110M 3M 5M -262M -123M 523M -232M -15M -36M -218M 295M 6M -18M 7M
cashAtEndOfPeriod 301M 191M 105M 238M 500M 623M 100M 62M 77M 113M 332M 59M 36M 54M
cashAtBeginningOfPeriod 191M 189M 100M 500M 623M 100M 332M 77M 113M 332M 36M 53M 54M 47M
operatingCashFlow 80M -47M -456M -67M -135M -149M -324M -85M -75M -84M -225M -59M -184M -158M
capitalExpenditure -857 000 0 -1M -779 000 -5M -357 000 -1M -339 000 -69 000 -35 000 -217 000 -33 000 -209 000 -334 000
freeCashFlow 79M -47M -457M -68M -140M -150M -326M -85M -75M -84M -225M -59M -184M -158M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-28 2023-03-03 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 19M 0 3000 -787 000 -2M
netCashProvidedByInvestingActivities -274M -503M 207M -5M 160M
netDebtIssuance 0 65M 50M 0 0
longTermNetDebtIssuance 0 65M 50M 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 397M 260M 255M 170M 4M
netCommonStockIssuance 397M 260M 255M 170M 4M
commonStockIssuance 397M 260M 255M 170M 4M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 338M 270M 8M 1M 667 000
netCashProvidedByFinancingActivities 735M 595M 313M 171M 5M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-04 ET (fiscal 2025 q3)
2025 q2
2025-08-05 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-07 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2022 q1
2022-05-09 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-04 09:11 ET
Madrigal Pharmaceuticals reported for 2025 q3
SEC form 8
2025-11-04 07:03 ET
Madrigal Pharmaceuticals published news for 2025 q3
SEC form 8
2025-11-04 07:03 ET
Madrigal Pharmaceuticals published news for 2025 q3
SEC form 10
2025-08-05 12:59 ET
Madrigal Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-05 11:05 ET
Madrigal Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-05 11:05 ET
Madrigal Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-30 10:30 ET
Madrigal Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-30 10:30 ET
Madrigal Pharmaceuticals published news for 2025 q2
SEC form 10
2025-05-01 12:53 ET
Madrigal Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-01 11:02 ET
Madrigal Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-01 11:02 ET
Madrigal Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Madrigal Pharmaceuticals reported for 2025 q1
SEC form 10
2025-02-26 09:09 ET
Madrigal Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-26 07:05 ET
Madrigal Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-26 07:05 ET
Madrigal Pharmaceuticals reported for 2024 q4
SEC form 10
2025-02-26 00:00 ET
Madrigal Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Madrigal Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Madrigal Pharmaceuticals published news for 2024 q4
SEC form 10
2024-10-31 09:02 ET
Madrigal Pharmaceuticals reported for 2024 q3
SEC form 8
2024-10-31 07:05 ET
Madrigal Pharmaceuticals reported for 2024 q3
SEC form 8
2024-10-31 07:05 ET
Madrigal Pharmaceuticals published news for 2024 q3
SEC form 10
2024-10-31 00:00 ET
Madrigal Pharmaceuticals reported for 2024 q3
SEC form 10
2024-08-07 08:58 ET
Madrigal Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-07 07:06 ET
Madrigal Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-07 07:06 ET
Madrigal Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Madrigal Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-07 09:00 ET
Madrigal Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-07 07:06 ET
Madrigal Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-07 07:06 ET
Madrigal Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Madrigal Pharmaceuticals reported for 2024 q1
SEC form 8
2024-02-28 07:01 ET
Madrigal Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 07:01 ET
Madrigal Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-28 06:32 ET
Madrigal Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Madrigal Pharmaceuticals published news for 2023 q4
SEC form 8
2023-11-06 08:31 ET
Madrigal Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-06 06:10 ET
Madrigal Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Madrigal Pharmaceuticals reported for 2023 q3
SEC form 6
2023-08-08 08:00 ET
Madrigal Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-08 06:50 ET
Madrigal Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Madrigal Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Madrigal Pharmaceuticals reported for 2023 q2
SEC form 6
2023-07-17 08:00 ET
Madrigal Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-30 08:00 ET
Madrigal Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-16 19:00 ET
Madrigal Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-16 18:54 ET
Madrigal Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Madrigal Pharmaceuticals reported for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Madrigal Pharmaceuticals reported for 2023 q1
SEC form 6
2023-03-03 16:17 ET
Madrigal Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-23 08:02 ET
Madrigal Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-23 06:32 ET
Madrigal Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-09 17:01 ET
Madrigal Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-10 17:00 ET
Madrigal Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-23 07:00 ET
Madrigal Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-19 08:42 ET
Madrigal Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-03 08:56 ET
Madrigal Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-03 08:01 ET
Madrigal Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q3
SEC form 6
2022-08-04 06:33 ET
Madrigal Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-04 06:31 ET
Madrigal Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q2
SEC form 6
2022-06-17 12:33 ET
Madrigal Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-09 12:55 ET
Madrigal Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-09 10:22 ET
Madrigal Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-09 06:33 ET
Madrigal Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Madrigal Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-02 11:40 ET
Madrigal Pharmaceuticals published news for 2022 q1
SEC form 10
2022-02-24 13:39 ET
Madrigal Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 08:01 ET
Madrigal Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q4
SEC form 6
2021-11-04 08:30 ET
Madrigal Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 06:07 ET
Madrigal Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q3
SEC form 6
2021-08-05 08:31 ET
Madrigal Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 06:51 ET
Madrigal Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-21 10:56 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-01 08:01 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-18 08:30 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-06 08:31 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 06:10 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-30 15:59 ET
Madrigal Pharmaceuticals published news for 2021 q1
SEC form 10
2021-02-25 11:05 ET
Madrigal Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-25 08:58 ET
Madrigal Pharmaceuticals published news for 2020 q4
SEC form 6
2020-11-05 09:20 ET
Madrigal Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-05 08:52 ET
Madrigal Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-05 06:06 ET
Madrigal Pharmaceuticals published news for 2020 q3